| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 86.55 | 0.69 (+0.80%) | 42.47 - 96.25 | 4.7 million (Above Avg) |
Market data as of 11:24AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 86.20 |
|---|---|
| Previous Close | 85.86 |
| Day's Range | 85.62 - 86.99 |
| Market Cap | 26.4B |
| Avg Volume (10 Day) | 1.3M |
| Price/Earnings (Trailing 12 Mo.) | 29.3x |
| Earnings Per Share (Trailing 12 Mo.) | 0.9 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
PR Newswire - Tuesday 06/18/2013 10:21 PM ET
Valeant Pharmaceuticals Prices Public Offering Of Common Shares
PR Newswire - Tuesday 06/18/2013 7:25 PM ET
Valeant Pharmaceuticals Announces Public Offering Of Common Shares
PR Newswire - Monday 06/17/2013 4:02 PM ET
Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
PR Newswire - Friday 06/07/2013 2:28 PM ET
Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
PR Newswire - Tuesday 05/28/2013 7:00 AM ET
Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion
PR Newswire - Monday 05/27/2013 8:00 AM ET
Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion
PR Newswire - Monday 05/27/2013 8:00 AM ET
Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
PR Newswire - Tuesday 05/21/2013 5:00 PM ET
| VRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 36.46% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 2.96 | |
| LT Debt/Equity | 2.88 | |
| Earnings Yield | 3.41% | |
| Price/Sales | 6.97 |
| Company | Last | Change |
|---|---|---|
| Elan Corporation PLC | 13.76 | -0.15% |
| Hospira Inc | 36.40 | -0.52% |
| Alkermes Plc | 29.44 | -1.57% |
| PetMed Express Inc | 13.44 | +0.37% |
| Flamel Technologies SA | 6.15 | -0.16% |
Data is delayed by at least 15 min.